News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen Class of 2024
Insights
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Jobs
Career Advice
Companies
Hotbeds
More
Employer Resources
Best Places to Work
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
677,370 Results
Type
Article (38710)
Company Profile (247)
Press Release (638413)
Section
Business (203356)
Career Advice (1974)
Deals (35347)
Drug Delivery (77)
Drug Development (80532)
Employer Resources (167)
FDA (15976)
Job Trends (14774)
News (343386)
Policy (32402)
Tag
Academia (2529)
Africa (710)
Alliances (48926)
Alzheimer's disease (1132)
Approvals (15922)
Arizona (169)
Artificial intelligence (64)
Asia (36701)
Australia (5968)
Bankruptcy (350)
Best Places to Work (11209)
Biosimilars (60)
Biotechnology (171)
C2C Services and Suppliers (78803)
California (1521)
Canada (829)
Cancer (319)
Career advice (1644)
Cell therapy (96)
China (109)
Clinical research (62891)
Collaboration (105)
Colorado (63)
Connecticut (59)
COVID-19 (2471)
Cystic fibrosis (71)
Data (124)
Diabetes (64)
Diagnostics (5941)
Drug pricing (59)
Earnings (83608)
Employer resources (140)
Europe (78389)
Events (107310)
Executive appointments (86)
FDA (16140)
Florida (207)
Funding (91)
Gene therapy (73)
GLP-1 (497)
Government (4282)
Healthcare (18569)
Hotbed/Location (480983)
Idaho (56)
Illinois (230)
Indiana (133)
Infectious disease (2495)
Inflammatory bowel disease (86)
Interviews (305)
IPO (16162)
Job creations (3620)
Job search strategy (1411)
Kansas (93)
Layoffs (388)
Legal (7827)
Lung cancer (69)
Manufacturing (71)
Maryland (336)
Massachusetts (1272)
Medical device (13012)
Medtech (13015)
Mergers & acquisitions (18989)
Metabolic disorders (213)
Michigan (114)
Minnesota (201)
Neuroscience (1241)
New Jersey (468)
New York (476)
NextGen Class of 2024 (6478)
Non-profit (4452)
North Carolina (554)
Northern California (693)
Obesity (132)
Ohio (96)
Opinion (167)
Patents (55)
Pennsylvania (511)
People (55685)
Pharmaceutical (59)
Phase I (19480)
Phase II (27699)
Phase III (20703)
Pipeline (91)
Postmarket research (2545)
Preclinical (8290)
Press Release (64)
Rare diseases (111)
Real estate (5881)
Recruiting (63)
Regulatory (21128)
Research institute (2300)
Resumes & cover letters (345)
South America (1084)
Southern California (624)
Startups (3554)
Texas (179)
United States (7261)
Vaccines (443)
Washington State (232)
Weight loss (116)
Date
Last 7 days (461)
Last 30 days (2176)
Last 365 days (37411)
2024 (24440)
2023 (40075)
2022 (51175)
2021 (55716)
2020 (54089)
2019 (46544)
2018 (35021)
2017 (32114)
2016 (31483)
2015 (37553)
2014 (31319)
2013 (26349)
2012 (28571)
2011 (29266)
2010 (27328)
677,370 Results for "cognate bioservices inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Biotech Beach
Avid Bioservices Earns Committed Badge from EcoVadis for Sustainability Performance
Avid Bioservices, Inc. announced that the company has achieved a Committed Badge from EcoVadis, one of the world’s most trusted providers of business sustainability ratings.
May 23, 2024
·
2 min read
Biotech Beach
Avid Bioservices to Participate at Upcoming May 2024 Investor Conferences
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, announced that the company will participate at two upcoming investor conferences.
May 7, 2024
·
1 min read
Press Releases
Avid Bioservices to Report Financial Results for Quarter and Fiscal Year Ended April 30, 2024, After Market Close on July 2, 2024
Avid Bioservices, Inc. today announced that it will report financial results for the quarter and fiscal year ended April 30, 2024, on July 2, 2024, after market close and will host a webcast at 1:30 PM Pacific Time (4:30 PM Eastern Time).
July 1, 2024
·
1 min read
Biotech Beach
Avid Bioservices Announces Pricing of Private Placement of Convertible Notes
Avid Bioservices, Inc., a dedicated biologics contract development and manufacturing organization, announced the pricing of $160 million aggregate principal amount of 7.00% Convertible Senior Notes due 2029.
March 7, 2024
·
5 min read
Business
Avid Bioservices Reports Financial Results for Third Quarter Ended January 31, 2024
Avid Bioservices, Inc. (NASDAQ: CDMO), a dedicated biologics contract development and manufacturing organization (CDMO) working to improve patient lives by providing high quality development and manufacturing services to biotechnology and pharmaceutical companies, today announced financial results for the third quarter and nine months ended January 31, 2024.
April 24, 2024
·
18 min read
Business
Avid Bioservices Announces Certain Preliminary Financial Results for Third Quarter Ended January 31, 2024
Avid Bioservices, Inc. (NASDAQ:CDMO) today announced preliminary earnings estimates for the third quarter and nine months ended January 31, 2024.
March 6, 2024
·
7 min read
Business
Cellipont Bioservices and Adva Biotechnology Collaborate to Optimize Cell Therapy Manufacturing with the ADVA X3® Platform
Cellipont Bioservices and Adva Biotechnology today announce its partnership with Adva Biotechnology marking the launch of the groundbreaking ADVA X3® platform in North America.
May 7, 2024
·
4 min read
Biotech Beach
Avid Bioservices Announces Proposed Private Placement of Convertible Notes - March 06, 2024
Avid Bioservices, Inc. announced that it intends to offer, subject to market conditions and other factors, $160 million aggregate principal amount of Convertible Senior Notes due 2029 in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Section 4 of the Securities Act of 1933, as amended.
March 6, 2024
·
3 min read
Business
Cellipont Bioservices Appoints Edwin Beale as Chief Commercial Officer
Cellipont Bioservices, a leading cell therapy Contract Development and Manufacturing Organization (CDMO), today announced the appointment of Edwin Beale as its new Chief Commercial Officer, effective immediately.
March 12, 2024
·
2 min read
BioMidwest
Cellipont Bioservices and Wugen Sign Agreement for the Clinical Manufacture of Wugen’s Off-the-shelf CAR-T Cellular Therapies
Cellipont Bioservices and Wugen, Inc., a clinical-stage biotechnology company developing allogeneic, off-the-shelf cell therapies to treat a broad range of hematological and solid tumor malignancies, today announced the signing of an agreement for the manufacturing of their CAR-T cell therapies.
March 14, 2024
·
2 min read
1 of 67,737
Next